Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans
Abstract
Synergy between fluvastatin, at clinically unachievable concentrations, and fluconazole against Candida albicans has been reported. The purpose of the present study was to evaluate the in-vitro activity of fluconazole alone and in combination with clinically achievable concentrations of pravastatin and fluvastatin against C. albicans. In-vitro susceptibility and synergy testing were performed against clinical isolates of C. albicans with fluconazole, pravastatin and fluvastatin. Both checkerboard method and time-kill studies were performed. MICs for fluconazole ranged from 0.5 (susceptible) to >256 mg/L (resistant) at 24 h. All isolates had MICs >2 mg/L for both statins. No synergy or antagonism was observed with fluconazole in combination with either agent against any isolate of C. albicans by the checkerboard assay or time-kill studies. Clinically achievable concentrations of pravastatin and fluvastatin did not affect the in-vitro activity of fluconazole against C. albicans.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Interaction was not demonstrated between PRA or FLV and fluconazole.
“however, interaction was not demonstrated between PRA or FLV and FCZ [23] .”
From Statins as antifungal agents (2011) · cites this paper as [23]
Research into azole-statin interactions has attracted renewed interest.
“In this context, studies on the interaction between azoles and statins have gained renewed attention.10,11,27,32,37”
Nash et al. found no synergism between pravastatin and fluconazole against C. albicans isolates.
“Similarly, Nash et al. found no synergism between pravastatin and fluconazole against C. albicans isolates.27”
Combination drug therapy against C. albicans in which FS is combined with azole drugs seems impractical due to the high concentrations of FS required for an inhibitory effect at physiological pH.
“However, a combination drug therapy against C. albicans in which FS is combined with the commonly prescribed azole drugs seems impractical due to the high concentrations of FS required for an inhibitory effect at physiological pH [2, 3].”
From Inhibition of<i>Candida albicans</i>by Fluvastatin Is Dependent on pH (2009) · cites this paper as [2]
The antifungal action of FS is synergistic with the action of other antifungal drugs.
“Inhibition of sterol synthesis by fluvastatin has an antifungal effect on the opportunistic yeast pathogen Candida albicans and at high concentrations; the antifungal action of FS is synergistic with the action of other antifungal drugs [2, 3].”
From Inhibition of<i>Candida albicans</i>by Fluvastatin Is Dependent on pH (2009) · cites this paper as [2]
FS has an antifungal effect on Candida albicans at high concentrations.
“Inhibition of sterol synthesis by fluvastatin has an antifungal effect on the opportunistic yeast pathogen Candida albicans and at high concentrations; the antifungal action of FS is synergistic with the action of other antifungal drugs [2, 3].”
From Inhibition of<i>Candida albicans</i>by Fluvastatin Is Dependent on pH (2009) · cites this paper as [2]
Cites
Still being checked.
Cited by
Sorted by citations
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541 · see citing works
Statins: a viable candidate for host-directed therapy against infectious diseases
Parihar, S. P., Guler, R., & Brombacher, F. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0094-3 · Cited by 155 · see citing works
Growth inhibition of<i>Candida</i>species and<i>Aspergillus fumigatus</i>by statins
Macreadie, I. G., Johnson, G., Schlosser, T., & Macreadie, P. I. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2006.00370.x · Cited by 136 · see citing works
Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations
Bidaud, A.-L., Schwarz, P., Herbreteau, G., & Dannaoui, É. (2021) · Journal of Fungi · doi:10.3390/jof7020113 · Cited by 97 · see citing works
Farnesol signalling in Candida albicans – more than just communication
Polke, M., Leonhardt, I., Kurzai, O., & Jacobsen, I. D. (2017) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2017.1337711 · Cited by 87 · see citing works
Nyilasi, I., Kocsubé, S., Krizsán, K., Galgóczy, L., Pesti, M., Papp, T., & Vágvölgyi, C. (2010) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.01972.x · Cited by 83 · see citing works
Antifungal activity of statins againstAspergillusspecies
Qiao, J., Kontoyiannis, D. P., Wan, Z., Li, R., & Liu, W. Y. (2007) · Medical Mycology · doi:10.1080/13693780701397673 · Cited by 69 · see citing works
Drug repurposing strategies in the development of potential antifungal agents
Zhang, Q., Liu, F., Zeng, M., Mao, Y., Song, Z., Mao, Y., & Song, Z. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11407-7 · Cited by 72 · see citing works
Sun, H., & Singh, N. (2009) · Clinical Infectious Diseases · doi:10.1086/597039 · Cited by 65 · see citing works
Antifungal Activity of Nonantifungal Drugs
Afeltra, J., & Verweij, P. E. (2003) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-003-0947-x · Cited by 63 · see citing works
Song, J. L., Lyons, C. N., Holleman, S., Oliver, B. G., & White, T. C. (2003) · Medical Mycology · doi:10.1080/1369378031000137233 · Cited by 62 · see citing works
Cabral, M. E., Figueroa, L. I. C., & Fariña, J. I. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2012.09.006 · Cited by 54 · see citing works
Systematic review of the in vitro effects of statins on oral and perioral microorganisms
Ting, M., Whitaker, E. J., & Albandar, J. M. (2015) · European Journal Of Oral Sciences · doi:10.1111/eos.12239 · Cited by 57 · see citing works
Zhou, Y., Yang, H., Zhou, X., Luo, H., Tang, F., Yang, J., Alterovitz, G., Cheng, L., & Ren, B. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-8959-8 · Cited by 49 · see citing works
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Kim, K., Zilbermintz, L., & Martchenko, M. (2015) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-015-0090-4 · Cited by 48 · see citing works
Nyilasi, I., Kocsubé́, S., Krizsán, K., Galgóczy, L., Papp, T., Pesti, M., Nagy, K., & Vágvölgyi, C. (2013) · Medical Mycology · doi:10.3109/13693786.2013.828160 · Cited by 44 · see citing works
Argenta, J. S., Alves, S. H., Silveira, F., Maboni, G., Zanette, R. A., Cavalheiro, A. S., Pereira, P. D. L., Pereira, D. I. B., Sallis, E. S. V., Pötter, L., et al. (2011) · Veterinary Microbiology · doi:10.1016/j.vetmic.2011.12.003 · Cited by 41 · see citing works
Tashiro, M., Kimura, S., Tateda, K., Saga, T., Ohno, A., Ishii, Y., Izumikawa, K., Tashiro, T., Kohno, S., & Yamaguchi, K. (2012) · Medical Mycology · doi:10.3109/13693786.2011.610037 · Cited by 36 · see citing works
Statins in candidemia: clinical outcomes from a matched cohort study.
Forrest, G. N., Kopack, A. M., & Perencevich, E. N. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-152 · Cited by 33 · see citing works
Rana, R., Sharma, R., & Kumar, A. (2019) · Current Molecular Medicine · doi:10.2174/1566524019666190520094644 · Cited by 32 · see citing works
Synergy Against Fungal Pathogens: Working Together is Better Than Working Alone
Musioł, R., Mrozek‐Wilczkiewicz, A., & Polański, J. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666131218094848 · Cited by 32 · see citing works
Venturini, T. P., Rossato, L. L., Spader, T. B., Alves, G. R. T., Azevedo, M. I., Weiler, C. B., Santúrio, J. M., & Alves, S. H. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.05.007 · Cited by 29 · see citing works
Arai, R., Sugita, T., & Nishikawa, A. (2005) · Mycoses · doi:10.1111/j.1439-0507.2004.01052.x · Cited by 29 · see citing works
Physiological adventures in Candida albicans : farnesol and ubiquinones
Nickerson, K. W., Gutzmann, D. J., Boone, C. H. T., Pathirana, R. U., & Atkin, A. L. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00081-22 · Cited by 26 · see citing works
Alternative treatment of fungal infections: Synergy with non‐antifungal agents
Rossato, L. L., dos Santos, M. C., Vitale, R. G., de Hoog, S., & Ishida, K. (2020) · Mycoses · doi:10.1111/myc.13203 · Cited by 27 · see citing works
In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans
Guo, N., Ling, G., Liang, X., Jin, J., Fan, J., Qiu, J., Song, Y., Huang, N., Wu, X., Wang, X., et al. (2010) · Mycoses · doi:10.1111/j.1439-0507.2010.01935.x · Cited by 23 · see citing works
Galgóczy, L. (2011) · World Journal of Clinical Infectious Diseases · doi:10.5495/wjcid.v1.i1.4 · Cited by 21 · see citing works
General metabolism of the dimorphic and pathogenic fungus Paracoccidioides brasiliensis.
Arraes, F. B. M., Benoliel, B., Burtet, R. T., Costa, P. L. N., Galdino, A. S., Lima, L. H. A., Marinho-Silva, C., Oliveira-Pereira, L., Pfrimer, P., Procópio, L., et al. (2005) · PubMed · Cited by 21 · see citing works
Effect of Statin Use on Outcomes of Adults with Candidemia
Cuervo, G., Garcia-Vidal, C., Nucci, M., Puchades, F., Fernández-Ruiz, M., Mykietiuk, A., Manzur, A., Gudiol, C., Pemán, J., Viasus, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077317 · Cited by 20 · see citing works
Andrade-Pavón, D., Ortiz-Álvarez, J., Sanchez‐Sandoval, E., Tamariz, J., Hernández, G., Ibarra, J. A., & Villa‐Tanaca, L. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.01.008 · Cited by 13 · see citing works
Andrade-Pavón, D., Cuevas‐Hernández, R. I., Trujillo-Ferrara, J. G., Hernández, G., Ibarra, J. A., & Villa‐Tanaca, L. (2017) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-017-2412-9 · Cited by 12 · see citing works
Is there a role for statins in fungal infections?
Bergman, P. W., & Björkhem-Bergman, L. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.856755 · Cited by 12 · see citing works
L’activité antifongique des statines
Lefebvre, M., ALshawa, K., & Dupont, B. (2010) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2010.05.007 · Cited by 12 · see citing works
Effect of different statins on the antifungal activity of polyene antimycotics
Nyilasi, I., Kocsubé́, S., Galgóczy, L., Papp, T., Pesti, M., & Vágvölgyi, C. (2010) · Acta Biologica Szegediensis · Cited by 10 · see citing works
Inhibition of<i>Candida albicans</i>by Fluvastatin Is Dependent on pH
Schmidt, M., Dzogbeta, S., & Boyer, M. P. (2009) · Research Letters in Biochemistry · doi:10.1155/2009/151424 · Cited by 7 · see citing works
MINIREVIEW Combination Antifungal Therapy
Johnson, J. R., Dougall, C. M., & Zeichner, L. O. (2004) · Cited by 7 · see citing works
Differential Sensitivity of the Species of Candida parapsilosis Sensu Lato Complex Against Statins
Szenzenstein, J., Gácser, A., Grózer, Z., Farkas, Z. J., Nagy, K., Vágvölgyi, C., Márki‐Zay, J., & Pfeiffer, I. (2013) · Mycopathologia · doi:10.1007/s11046-013-9689-1 · Cited by 6 · see citing works
Eshkaleti, M. N., Kordbacheh, P., Hashemi, S. J., Falahati, M., Zaini, F., Mirhendi, H., Safara, M., & Hosseinpoor, L. (2019) · Iranian Journal of Public Health · doi:10.18502/ijph.v48i5.1812 · Cited by 6 · see citing works
Andrade-Pavón, D., Sanchez‐Sandoval, E., Tamariz, J., Ibarra, J. A., Hernández-Rodríguez, C., & Villa‐Tanaca, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316868 · Cited by 3 · see citing works
Saber-Moghaddam, N., Nodeh, M. M., Ghavami, V., Rahimi, H., Azimi, S. A., Seddigh‐Shamsi, M., Kamandi, M., Allahyari, A., Shariatmaghani, S. S., Elyasi, S., et al. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02892-w · Cited by 1 · see citing works
The effect of statin use on incident immune-mediated and infectious conditions among U.S. veterans
Cirillo, D. J. (2008) · doi:10.17077/etd.177vmb1k · Cited by 1 · see citing works
Drug Repurposing Strategies in the Discovery of Antifungal AgentsPreprint
Zhang, Q., Liu, F., Zeng, M., Xin, C., Zhang, J., Mao, Y., & Song, Z. (2021) · Preprints.org · doi:10.20944/preprints202102.0405.v1 · Cited by 1 · see citing works
Repurposing FDA approved drugs against the human fungal pathogen, Candida
Kim, K. S., & Martchenko, M. (2015)
John Wiley & Sons, L. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.661
- Authors
- NASH, J. D., BURGESS, D. S., & TALBERT, R. L.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- ORCID
- BURGESS, DAVID S.
- Venue
- Journal of Medical Microbiology
- Publisher
- Microbiology Society
- Published
- 2002-02-01
- Volume
- 51
- Issue
- 2
- Pages
- 105-109
- ISSN
- 0022-2615 (ISSN-L)
- 1473-5644
- OpenAlex
- W1905077086
- Cited by
- 44
- References
- 0
- Citations by year
- 2024: 1 · 2023: 2 · 2021: 3 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 2 · 2015: 3 · 2014: 1 · 2013: 4 · 2012: 2
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medical Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Keywords
- fluvastatin, pravastatin, fluconazole, Candida albicans, statins, antifungal synergy, antifungal resistance, in vitro susceptibility, time-kill kinetics, checkerboard assay
- MeSH terms
- Fluvastatin, Antifungal Agents, Candida albicans, Drug Synergism, Fatty Acids, Monounsaturated, Indoles, Microbial Sensitivity Tests, Fluconazole, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
